Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
8.34
+0.02 (0.24%)
Nov 6, 2026, 4:00 PM EST - Market closed
Atrium Therapeutics Revenue
In the year 2025, Atrium Therapeutics had annual revenue of $18.76M with 72.11% growth. Atrium Therapeutics had revenue of $860.00K in the quarter ending December 31, 2025, a decrease of -71.07%. That makes Atrium Therapeutics the 30,247th largest company in the world by revenue and 4,001st in the United States.
Revenue (ttm)
$18.76M
Revenue Growth
+72.11%
P/S Ratio
3.98
Revenue / Employee
n/a
Employees
n/a
Market Cap
142.66M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.76M | 7.86M | 72.11% |
| Dec 31, 2024 | 10.90M | 1.34M | 13.99% |
| Dec 31, 2023 | 9.56M | 336.00K | 3.64% |
| Dec 31, 2022 | 9.22M | -102.00K | -1.09% |
| Dec 31, 2021 | 9.33M | 2.54M | 37.41% |
| Dec 31, 2020 | 6.79M | 4.47M | 192.67% |
| Dec 31, 2019 | 2.32M | 1.94M | 511.87% |
| Dec 31, 2018 | 379.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Cue Biopharma | 37.66M |
| Adagene | 9.29M |
| Compass Therapeutics | 850.00K |
| Spruce Biosciences | 697.00K |
| Veraxa Biotech AG | 29.54K |
RNA News
- 6 days ago - Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026 - PRNewsWire
- 11 days ago - Atrium Therapeutics price target lowered to $20 from $25 at H.C. Wainwright - TheFly
- 12 days ago - Atrium Therapeutics doses first patient in Corventis clinical trial - TheFly
- 12 days ago - Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome - PRNewsWire
- 17 days ago - Atrium Therapeutics initiated with a Buy at Roth Capital - TheFly
- 19 days ago - Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 19 days ago - Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing - PRNewsWire
- 4 weeks ago - Atrium Therapeutics announces $50M private placement - TheFly